Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs
Biotech has aligned its internal focus on CAR NKs, but may partner elsewhere
The latest signal of Bayer’s growing interest in gene and cell therapies is its investment in synthetic biology company Senti, whose gene circuit technology gives the biotech both an internal pipeline and a partnering opportunity.
The pharma’s Leaps by Bayer venture arm led a $105 million series B round Wednesday for Senti, which was co-founded by CEO Tim Lu...